← All candidates
13 insider filings on record.
32 filings on record.
GOSSGossamer Bio, Inc.
NasdaqGS · Healthcare · $66.97M
$10.96
+5.59% · Sep 16
13 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily◆ 4 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what GOSS ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$66.97M
Float
3.8M
63% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
1.3
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Milligan Sandra
Bought $50.0K on Aug 19 — 26,050 sh @ $1.92, held direct, 45% of their stake.
1 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
7 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
8 more transactions on Pro →Context
Wall St
$132.48 avg target
+1108.8% vs today · 5 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 4 quarters beat
Q2 '26−$8.17 act+$1.82
Q1 '26−$16.00 act−$2.36
Q4 '25−$16.80 act−$1.15
Q3 '25−$16.80 act−$1.03
Coverage
Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?Insider Monkey · 2w agoGossamer Bio announces $250m in funding to advance seralutinibPharmaceutical Technology · 3w agoGossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA ApprovalInvestorsHub · 3w agoGossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-BellMT Newswires · 3w ago
The file stays open
32 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice